Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention.
Oncol Rep
; 8(2): 373-9, 2001.
Article
de En
| MEDLINE
| ID: mdl-11182059
ABSTRACT
Studies were performed to determine the effects of moderate decreases in body weight gain on mammary carcinogenesis. The levels of depressions in weight gain were those often observed in the evaluation of chemopreventive agents. In the first experiment, the effects of acute and chronic reductions of body weight gain when started after carcinogen treatment were examined in young rats (MNU at 50 days of age). Significant decreases (36%) in mammary cancers occurred in groups of rats that underwent a 12% acute reduction in body weight gain as compared with ad libitum controls. In contrast, chronic weight reductions of up to 12% had minimal effects on cancer multiplicities, while a 15% chronic reduction significantly decreased cancer numbers (26%). A second experiment evaluated the efficacy of toremifene (7.0 mg/kg diet), an estrogen/anti-estrogen, and the effect of toremifene-matched body weight gain reduction that occurred during the study. Toremifene caused a chronic reduction in body weight that resulted in a 10% decrease in final body weight at the end of the study. While toremifene-treated rats exhibited a 67% decrease in the number of mammary cancers, the
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Adénocarcinome
/
Prise de poids
/
Anticarcinogènes
/
Torémifène
/
Modulateurs sélectifs des récepteurs des oestrogènes
/
Tumeurs expérimentales de la mamelle
Type d'étude:
Prognostic_studies
Limites:
Animals
Langue:
En
Journal:
Oncol Rep
Sujet du journal:
NEOPLASIAS
Année:
2001
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique